To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

PARP1 is required for adh… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

PARP1 is required for adhesion molecule expression in atherogenesis.

Journal article
Authors Tobias von Lukowicz
Paul O Hassa
Christine Lohmann
Jan Borén
Vincent Braunersreuther
François Mach
Bernhard Odermatt
Monika Gersbach
Giovanni G Camici
Barbara E Stähli
Felix C Tanner
Michael O Hottiger
Thomas F Lüscher
Christian M Matter
Published in Cardiovascular research
Volume 78
Issue 1
Pages 158-66
ISSN 0008-6363
Publication year 2008
Published at Wallenberg Laboratory
Institute of Medicine, Department of Molecular and Clinical Medicine
Pages 158-66
Language en
Links dx.doi.org/10.1093/cvr/cvm110
Keywords Animals, Apolipoproteins E, genetics, metabolism, Atherosclerosis, enzymology, immunology, pathology, prevention & control, Cell Adhesion Molecules, metabolism, Cholesterol, blood, Disease Models, Animal, E-Selectin, metabolism, Enzyme Inhibitors, pharmacology, Inflammation, enzymology, immunology, pathology, prevention & control, Inflammation Mediators, blood, Macrophages, pathology, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Necrosis, Nitric Oxide Synthase Type II, metabolism, P-Selectin, metabolism, Phenanthrenes, pharmacology, Poly(ADP-ribose) Polymerases, antagonists & inhibitors, genetics, metabolism, T-Lymphocytes, pathology, Vascular Cell Adhesion Molecule-1, metabolism
Subject categories Medical and Health Sciences

Abstract

AIMS: Atherosclerosis is the leading cause of death in Western societies and a chronic inflammatory disease. However, the key mediators linking recruitment of inflammatory cells to atherogenesis remain poorly defined. Poly(ADP-ribose) polymerase 1 (PARP1) is a nuclear enzyme, which plays a role in acute inflammatory diseases. METHODS AND RESULTS: In order to test the role of PARP in atherogenesis, we applied chronic pharmacological PARP inhibition or genetic PARP1 deletion in atherosclerosis-prone apolipoprotein E-deficient mice and measured plaque formation, adhesion molecules, and features of plaque vulnerability. After 12 weeks of high-cholesterol diet, plaque formation in male apolipoprotein E-deficient mice was decreased by chronic inhibition of enzymatic PARP activity or genetic deletion of PARP1 by 46 or 51%, respectively (P < 0.05, n >or= 9). PARP inhibition or PARP1 deletion reduced PARP activity and diminished expression of inducible nitric oxide synthase, vascular cell adhesion molecule-1, and P- and E-selectin. Furthermore, chronic PARP inhibition reduced plaque macrophage (CD68) and T-cell infiltration (CD3), increased fibrous cap thickness, and decreased necrotic core size and cell death (P < 0.05, n >or= 6). CONCLUSION: Our data provide pharmacological and genetic evidence that endogenous PARP1 is required for atherogenesis in vivo by increasing adhesion molecules with endothelial activation, enhancing inflammation, and inducing features of plaque vulnerability. Thus, inhibition of PARP1 may represent a promising therapeutic target in atherosclerosis.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?